Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Smoking affects the interferon beta treatment response in multiple sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Imaging markers of small vessel disease and brain frailty, and outcomes in acute stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Author response: Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark

    Research output: Contribution to journalComment/debateResearchpeer-review

  4. Fat oxidation is impaired during exercise in lipin-1 deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Secular trends in risk of stroke according to body mass index and blood pressure, 1976-2017

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Validation of suPAR turbidimetric assay on Cobas® (c502 and c702) and comparison to suPAR ELISA

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. MAIT cell subtypes in multiple sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Early Intrathecal T Helper 17.1 Cell Activity in Huntington Disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Intoxicationer og ernæringsdeficit

    Research output: Chapter in Book/Report/Conference proceedingBook chapterEducation

View graph of relations

OBJECTIVE: To investigate whether smoking in patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon beta (IFN-β) is associated with the relapse rate and whether there is an interaction between smoking and human leukocyte antigen (HLA)-DRB1*15:01, HLA-A*02:01, and the N-acetyltransferase-1 (NAT1) variant rs7388368A.

METHODS: DNA from 834 IFN-β-treated patients with RRMS from the Danish Multiple Sclerosis Biobank was extracted for genotyping. Information about relapses from 2 years before the start of treatment to either the end of treatment or the last follow-up visit was obtained from the Danish Multiple Sclerosis Treatment Register. Smoking information came from a comprehensive questionnaire.

RESULTS: We found that the relapse rate in patients with RRMS during IFN-β treatment was higher in smokers compared to nonsmokers, with an incidence rate ratio (IRR) of 1.20 (95% confidence interval [CI] 1.021-1.416, p = 0.027) and with an IRR increase of 27% per pack of cigarettes per day (IRR 1.27, 95% CI 1.056-1.537, p = 0.012). We found no association or interaction with HLA and the NAT1 variant.

CONCLUSION: In this observational cohort study, we found that smoking is associated with increased relapse activity in patients with RRMS treated with IFN-β, but we found no association or interaction with HLA or the NAT1 variant.

Original languageEnglish
JournalNeurology
Volume90
Issue number7
Pages (from-to)e593-e600
ISSN0028-3878
DOIs
Publication statusPublished - 13 Feb 2018

ID: 56324276